Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunasin Regimen for ALS
NCT02709330Phase 2Completed
- Start
- Apr 2016
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial. Primary endpoint: Revised ALS Functional Rating Scale at 12 months. Started Apr 2016; status: completed.
Beyond the preview
Go deeper on NCT02709330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709330.